Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?
Davide Franceschini(IRCCS Humanitas Research Hospital), Marta Scorsetti(Humanitas University), Pierina Navarria(IRCCS Humanitas Research Hospital), Ciro Franzese(IRCCS Humanitas Research Hospital), Armando Santoro(IRCCS Humanitas Research Hospital), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), A.M. Ascolese(IRCCS Humanitas Research Hospital), Fiorenza De Rose
Cited by 32
Related Papers
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821